⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255114 | 0.84 | — | — | |
| SCHEMBL10703664 | 0.82 | — | — | |
| SCHEMBL12714080 | 0.74 | — | — | |
| SCHEMBL1106713 | 0.73 | — | — | |
| SCHEMBL9348883 | 0.71 | CA1 (0.42) | — | |
| SCHEMBL9348894 | 0.71 | CA1 (0.42) | — | |
| SCHEMBL4365428 | 0.71 | CA1 (0.42) | — | |
| SCHEMBL981359 | 0.70 | — | — | |
| SCHEMBL13928219 | 0.70 | — | — | |
| SCHEMBL10697669 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230231200-A1 | MIXED ELECTROLYTE FOR LI-S BATTERY | UNITED STATES DEPARTMENT OF ENERGY | 2023-07-20 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2021024994-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2021-02-11 | — | — | WO | disclosed |
| US-20180133177-A1 | Treatment of NASH with Gemcabene | NEUROBO PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180064671-A1 | Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease | GLAS AMERICAS LLC | 2018-03-08 | — | — | US | disclosed |
| US-9855240-B2 | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170298038-A1 | PROCESS FOR THE PREPARATION OF GAMMA-VALEROLACTONE BY CATALYTIC HYDROGENATION OF LEVULINIC ACID USING Ru-BASED CATALYSTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-10-19 | — | — | US | disclosed |
| US-20170172955-A1 | Treatment of Mixed Dyslipidemia | NEUROBO PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-8084498-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110111345-A1 | SILICON CONTAINING COATING COMPOSITIONS AND METHODS OF USE | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7713935-B2 | Compounds that modulate TRH actions | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2010-05-11 | — | — | US | disclosed |
| US-7378397-B2 | TRH-degrading ectoenzyme inhibitors | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2008-05-27 | — | — | US | disclosed |
| US-7335689-B2 | for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070265202-A1 | Compounds That Modulate Trh Actions | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE O (IE) | 2007-11-15 | — | — | US | disclosed |
| WO-2006038206-A2 | COMPOUNDS THAT MODULATE TRH ACTIONS AND INHIBIT THE TRH-DEGRADING ENZYME | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2006-04-13 | — | — | WO | disclosed |